https://ir.corbuspharma.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_dc5231ac157b9ee4fb322b64fcb7a082/corbuspharma/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.corbuspharma.com/news-events/press-releases/detail/463/corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer Tue, 07 Apr 26 08:00:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/463/corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer https://ir.corbuspharma.com/news-events/press-releases/detail/462/corbus-pharmaceuticals-to-participate-in-the-bmo-2026-metabolic-health-summit Wed, 18 Mar 26 08:00:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/462/corbus-pharmaceuticals-to-participate-in-the-bmo-2026-metabolic-health-summit https://ir.corbuspharma.com/news-events/press-releases/detail/461/corbus-pharmaceuticals-reports-q4-and-2025-financial-results-and-provides-a-corporate-update Mon, 09 Mar 26 07:30:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/461/corbus-pharmaceuticals-reports-q4-and-2025-financial-results-and-provides-a-corporate-update https://ir.corbuspharma.com/news-events/press-releases/detail/460/corbus-pharmaceuticals-to-present-at-the-36th-annual-oppenheimer-healthcare-life-sciences-conference Thu, 12 Feb 26 08:00:00 -0500 https://ir.corbuspharma.com/news-events/press-releases/detail/460/corbus-pharmaceuticals-to-present-at-the-36th-annual-oppenheimer-healthcare-life-sciences-conference https://ir.corbuspharma.com/news-events/press-releases/detail/459/corbus-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference Mon, 05 Jan 26 07:30:00 -0500 https://ir.corbuspharma.com/news-events/press-releases/detail/459/corbus-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference https://ir.corbuspharma.com/news-events/press-releases/detail/458/corbus-pharmaceuticals-reports-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913-for-the-treatment-for-obesity-demonstrating-favorable-safety-profile-and-emerging-evidence-of-weight-loss Thu, 11 Dec 25 07:00:00 -0500 https://ir.corbuspharma.com/news-events/press-releases/detail/458/corbus-pharmaceuticals-reports-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913-for-the-treatment-for-obesity-demonstrating-favorable-safety-profile-and-emerging-evidence-of-weight-loss https://ir.corbuspharma.com/news-events/press-releases/detail/457/corbus-pharmaceuticals-to-report-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913for-the-treatment-for-obesity-on-thursday-december-11-2025 Wed, 10 Dec 25 16:01:00 -0500 https://ir.corbuspharma.com/news-events/press-releases/detail/457/corbus-pharmaceuticals-to-report-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913for-the-treatment-for-obesity-on-thursday-december-11-2025 https://ir.corbuspharma.com/news-events/press-releases/detail/456/corbus-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update Wed, 12 Nov 25 08:00:00 -0500 https://ir.corbuspharma.com/news-events/press-releases/detail/456/corbus-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update https://ir.corbuspharma.com/news-events/press-releases/detail/455/corbus-pharmaceuticals-to-participate-in-upcoming-investor-conferences Thu, 06 Nov 25 08:00:00 -0500 https://ir.corbuspharma.com/news-events/press-releases/detail/455/corbus-pharmaceuticals-to-participate-in-upcoming-investor-conferences https://ir.corbuspharma.com/news-events/press-releases/detail/454/corbus-pharmaceuticals-announces-pricing-of-public-offering Fri, 31 Oct 25 02:40:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/454/corbus-pharmaceuticals-announces-pricing-of-public-offering